Abstract: A powder mixture for oral delivery of active ingredients includes a population of particles and one or more active ingredients, the population of particles including at least two types of sugar alcohol particles. At least one of the at least two types of sugar alcohol particles takes the form of i) non-directly compressible (non-DC) sugar alcohol particles or ii) directly compressible (DC) sugar alcohol particles that are not granulated sugar alcohol particles. At least one of the at least two types of sugar alcohol particles has a particle size with more than 50% of the particles being below 250 microns, and at least one of the at least two types of sugar alcohol particles is present in an amount of at least 20% by weight of the powder mixture.

Abstract: Disclosed herein are oral hygiene compositions, dental flossing material, and methods of treatment using the same. In some embodiments, the oral hygiene composition comprises a remineralization agent, a prebiotic agent, and an alkalizing agent.

Abstract: The present disclosure provides protein-enriched, tobacco-containing products, suitable for use as oral formulations. Products of the present disclosure typically include at least one tobacco material (e.g., a particulate tobacco material or a tobacco-derived extract), at least one protein-enriched material (e.g., a tobacco-derived protein-enriched material), and at least one sugar alcohol.

Abstract: Systems and methods for monitoring of biometric and contextual variables to assist in screening for, quantification of, and prediction of smoking behavior, and for assisting in smoking cessation are described.

Abstract: The present invention relates to a pharmaceutical composition for treating and preventing gingivoperiodontitis or peri-implantitis, comprising, as effective components, sodium ethylenediaminetetra acetate, cetylpyridinium chloride, octyl phenol ethoxylate, and sodium bicarbonate. The composition according to the present invention can effectively eliminate bacteria causing gingivoperiodontitis and peri-implantitis, thereby alleviating inflammation, and furthermore, an interdental brush coated with the composition is convenient to apply to gaps between teeth, dental implants, orthodontic appliances, etc. and thus can be used to treat and prevent gingivoperiodontitis and peri-implantitis conveniently at home.

Abstract: The present disclosure provides a chlorhexidine-cyclamate complex having a formula [C22H32Cl2N10][C6H12NO3S]2 having antibacterial and antiplaque properties, together with oral care compositions comprising the complex, and methods of making and using these complexes and compositions.

Abstract: Methods and systems of enhancing an electronic interaction between a behavioral-modification program and a user in the program by providing customized content specific to the user. The systems and methods allow for coach-counselor assistance to the individual-user or for automated content delivery.

Abstract: The invention relates to an oral nicotine formulation for use in the alleviation of nicotine craving, the formulation comprising a content of nicotine and a content of a pH regulating agent, wherein the formulation provides a peak saliva concentration of nicotine of more than 0.3 mg/mL and a peak saliva pH of more than 7.5 during the first 120 seconds upon oral administration.

Abstract: A soluble fiber lozenge in includes a body that is partially or wholly receivable in an oral cavity. The body includes a soluble-fiber matrix and one or more additives in the soluble-fiber matrix. A soluble fiber lozenge provided herein includes at least 40 weight percent of soluble fiber. Soluble fiber in soluble fiber lozenge can include maltodextrin. The soluble fiber lozenge is adapted to release one or more additives from the body when the body is received within the oral cavity of a consumer and exposed to saliva. A method of making soluble fiber lozenges includes forming a molten mixture of at least 40 weight percent soluble fiber, one or more additives, and less than 15 weight percent water while maintaining a mixture temperature of less than 200° C. and portioning the molten mixture into a plurality of soluble fiber lozenges.

Abstract: The present invention discloses a gradient slow-release active composite film and a preparation method thereof. The active composite film, from inside to outside, is composed of an antioxidative hygroscopic internal layer, at least one gradient anti-microbial antioxidative intermediate layer and at least one waterproof external layer; wherein the antioxidative hygroscopic internal layer is prepared by an alcohol-soluble protein-water-soluble protein substrate and a water-soluble antioxidant; the gradient anti-microbial antioxidative intermediate layer is prepared by an alcohol-soluble protein-water-soluble protein substrate and a lipid-soluble plant essential oil and a water-soluble antioxidant, wherein a mass ratio of the alcohol-soluble protein to the water-soluble protein is (1-2):(1-2); and the waterproof external layer is composed of a hydrophobic alcohol-soluble protein layer.

Abstract: The present disclosure is directed to confectionery products, such as compressed mint tablets, that comprise menthol and eucalyptol. In certain embodiments, the menthol is encapsulated. The confectionery products deliver a strong initial cooling impact, and have extended storage stability in high humidity environments.

Abstract: The invention relates to a chewable medicated composition comprising simethicone as the sole active ingredient, and at least one gelling agent.

Abstract: Compositions that include: from 5 wt-% to 70 wt-% of one or more plant based oils based on the total weight of the composition; from 35 wt-% to 95 wt-% of an aqueous phase based on the total weight of the composition; not greater than 7.5 wt-% of one or more surfactants based on the total weight of the composition; and not greater than 3 wt-% of a viscosity modifier of, wherein the composition has a pH from 4.5 to 9.5, the composition is an oil in water (o/w) emulsion, and the composition is edible. Methods of utilizing disclosed compositions are also included.

Abstract: The present invention is directed to a medicinal composition, and more particularly, to a composition of chlorhexidine to treat lesions, particularly lesions caused by cold sores and herpes. The composition comprises chlorhexidine as the active ingredient. The composition also comprises a component for pain relief and a component for anti-inflammation. These three components, which act efficaciously in concert, are then combined with a suitable emollient or vehicle to form a topical formulation effective to treat the symptoms of cold sores and herpes. The composition may be formulated as an over-the-counter (OTC) topical formulation.

Abstract: This document provides methods and systems for stabilizing nicotine and incorporating nicotine into one or more oral products. This document also provides oral products. Nicotine can be stabilized by mixing liquid nicotine with cellulosic fiber such that the liquid nicotine absorbs into pores of the cellulosic fiber to form a cellulosic fiber-nicotine mixture. In some cases, a cellulosic fiber-nicotine mixture can be combined with one or more binders and molded into an oral product.

Abstract: Provided herein are compositions comprising nicotine, or a salt thereof, and pilocarpine, or a salt thereof, useful for reducing the use of betel quid and/or achieving betel quid cessation (e.g., replacement therapy). Also provided herein are methods of using the compositions in reducing the risk of developing or reducing the progression of a disease (e.g., cancer, oral disease, neurological disease, or painful condition). Compositions of the present invention may be administered to a subject with an addiction, e.g., a betel quid addiction, areca nut addiction, and/or nicotine addiction.

Abstract: Provided herein are methods of delivering transgenes to an eye of a subject comprising the use of pharmaceutical compositions having one or more polynucleotides suitable for enhancing, increasing, augmenting, and/or supplementing the levels of the transgene in the eye. Also provided herein are methods of correcting vision loss in a subject in need thereof comprising the use of the pharmaceutical compositions described herein.

Abstract: The disclosure provides chewable nicotine formulations comprising an orally-acceptable nicotine salt, an orally-acceptable alcohol, flavor components, and an orally-acceptable binder in a water-permeable, water-insoluble pouch, together with methods of making and using the same.

Abstract: Flavour modifying composition comprising one or more flavour modifying compounds of Formula I, product comprising said flavour modifying composition, use of said flavour modifying composition for modifying taste perception in foodstuffs and beverages and method of improving taste perception in a foodstuff or beverage comprising adding said flavour modifying composition to said foodstuff or beverage.

Abstract: A gel composition is provided, including an alkaloid compound, or a cannabinoid compound, or both an alkaloid compound and a cannabinoid compound; glycerol; a viscosifying agent; a hydrogen-bond crosslinking gelling agent; and an ionic crosslinking gelling agent; and an acid.

Abstract: Color indicating chewing gum compositions comprising one or more color compounds are provided. The compositions demonstrate a visual color or shade change from start of chewing to the end of chewing and provide oral health benefits. Methods of producing a color changing chewing gum are also provided.

Abstract: The present invention relates to a starch-free soft chew formulation for oral delivery of at least one active ingredient to an animal, and a starch-free soft chew containing the formulation and at least one active ingredient. The starch-free soft chew includes one or more active ingredients and excipients, such as a bulking agent, a flavoring agent, a humectant, a preservative, an antioxidant, and a lubricant, but no added water. In addition, the invention relates to a composition of starch-free, non-water excipients for use in the final dosage form of a soft chew for oral administration of at least one active ingredient to an animal. Also provided are processes for making the starch-free soft chew formulation and the starch-free soft chew.

Abstract: The present invention is directed to a dry suspension for reconstitution containing Tecovirimat (ST-246) powder and simethicone. The dry suspension is dispersed in water to provide an aqueous pharmaceutical suspension formulation for oral administration for treating orthopoxvirus infections and/or eczema vaccinatum. The suspension formulation exhibits excellent stability and good dissolution and has an improved taste and texture.

Abstract: The disclosure provides chewable nicotine formulations comprising an orally-acceptable nicotine salt, an orally-acceptable alcohol, flavor components, and an orally-acceptable binder in a water-permeable, water-insoluble pouch, together with methods of making and using the same.

Abstract: This invention relates to a chocolate or chocolate substitute composition or product comprising (a) at least compound to be delivered to a subject; (b) a chocolate or chocolate substitute matrix and at least (i) a masking agent or (ii) a firming agent, wherein the composition or product is substantially stable.

Abstract: The present disclosure provides a chlorhexidine-cyclamate complex having a formula [C22H32Cl2N10][C6H12NO3S]2 having antibacterial and antiplaque properties, together with oral care compositions comprising the complex, and methods of making and using these complexes and compositions.

Abstract: A process for obtaining an increase in the concentration and/or production of milk protein and/or improving reproductive performance. The process includes administering to a mammal a composition including at least one unsaturated fatty acid, or a derivative thereof, and at least one feed supplement, wherein the combination is administered in an amount such that the mammal absorbs 1 g to 95 g of the at least one unsaturated fatty acid, or the derivative thereof, per day.

Abstract: The present invention relates to products and methods for treatment of narcotic dependence in a user. The invention more particularly relates to self-supporting dosage forms which provide an active agent for treating narcotic dependence while providing sufficient buccal adhesion of the dosage form.

Abstract: A synthetic nicotine composition comprising synthetic nicotine, a synthetic nicotine salt and a synthetic nicotine derivative, wherein the synthetic nicotine, the synthetic nicotine salt, and the synthetic nicotine derivative are in mass percentage; the synthetic nicotine accounts for 1-20%, the synthetic nicotine salt accounts for 30-70%, and the synthetic nicotine derivative accounts for 20-50%; and the synthetic nicotine is one or more of S-nicotine and a mixture of R-nicotine containing a racemate and S-nicotine.

Abstract: The invention relates to an avocado extract rich in polyphenols, containing at least 10% by weight of polyphenols, expressed in gallic acid equivalent relative to the dry extract obtained, wherein said polyphenols contain procyanidins, cafeic acid and cafeic acid derivatives, typically in a proportion of at least 70% by weight, expressed in gallic acid equivalent relative to the total polyphenol content by weight. The invention also relates to a composition comprising an extract according to the invention as active agent and a suitable excipient. The invention also relates to such a composition or such an extract for use thereof in preventing or treating disorders or pathological conditions of the skin, the mucous membranes or the superficial body growths.

Abstract: The invention provides an oral pharmaceutical composition, optionally in dose unit form, comprising a lipophilic drug substance in dispersion in a physiologically tolerable aqueous carrier, preferably an aqueous gel, wherein said drug substance contains a functional electrostatic group having a pKa value of from 2 to 10, characterised in that said aqueous carrier has a pH at least 0.3 below or above said pKa value, said pH being below said pKa where said group is acidic and above said pKa where said group is basic.

Abstract: A water-soluble composition containing rutin, L-arginine, and an alkali salt of ascorbic acid in which the molar ratio between the rutin, L-arginine, and the alkali salt of ascorbic acid is 1:1.6-3.0:0.1-2.0.

Abstract: Gummy dosage forms comprising gummy compositions for nutritional supplementation, methods for providing nutritional supplementation, and kits comprising gummy compositions for nutritional supplementation are disclosed. Such gummy compositions for nutritional supplementation may provide improved patient compliance relative to non-gummy compositions for nutritional supplementation. These gummy compositions can be used to administer one or more vitamins, minerals, or trace elements.

Abstract: The present invention relates to compositions for mineralizing a dental surface, in particular tooth enamel. Methods of mineralizing hypomineralized lesions (including subsurface lesions) in the tooth enamel caused by dental caries, dental corrosion and fluorosis are also provided. In particular, the invention relates to a method of mineralizing a dental surface or subsurface comprising contacting the dental surface or subsurface with a compound that is capable of increasing or maintaining the pH of a solution and a mineralizing agent.

Abstract: The present invention relates to a skin massage gel which does not cause skin irritation because it does not contain dark brown sugar crystals and which can be safely used because it includes only natural materials, and a method of preparing the same. The method includes the steps of: (1) adding 8-12 parts by weight of malt powder made from dehusked malt to 100 parts by weight of rice wine, followed by heating while stirring in one direction; (2) filtering the heated solution using a filter; (3) adding 80-120 parts by weight of dark brown sugar to the filtered solution, followed by heating while stirring; (4) adding 25-35 parts by weight of honey to the solution, followed by heating; (5) adding 0.004-0.006 parts by weight of gold powder to the solution, followed by heating; and (6) aging the solution at room temperature.

Abstract: The present invention relates to a lozenge dosage form having a disintegrative tablet portion and a candy glass shell portion.

Abstract: An improved method for manufacture of chewing gums containing active ingredient(s) that preserves the efficacy of the active ingredient(s) by avoiding exposure to high heat and extreme cold during milling that can otherwise degrade the active's efficacy. A chewing gum base is used, along with one or more therapeutically-active ingredients, one or more sweeteners (alcohol-based and/or natural), and one or more flavorings and optional flavor modifiers. The method generally comprises heating the gum base in ovens to melt the gum base. Separately, the active ingredient(s), sweeteners and flavorings are combined in a mixer. The melted gum base is added to the mixer and cools to produce a particulate mixture. As mixing continues the mass cools to room temperature and forms granular pieces. The granular pieces are ground into a powder at room temperature, mixed at room temperature with tableting excipients, and tableted. Several variations on the foregoing are also described.

Abstract: The present invention relates to an oral pharmaceutical composition for drugs with a high dosage regimen, specifically, ion exchange resins and bulk-forming laxatives. Said composition comprises the combination of a liquid oily component and a texturizing agent, giving the composition good organoleptic properties that allow taking drugs with a high dosage regimen without the usual problems associated with their poor palatability. The invention also relates to a method for preparing said composition and to the use thereof for the treatment of various pathologies. Furthermore, the invention also relates to an adduct formed between a polyol and an ion exchange resin, to a method for preparing it, and to the use thereof to improve resin palatability.

Abstract: An aqueous composition useful for producing capsules shells comprises a) at least one dispersed esterified cellulose ether comprising (i) groups of the formula —C(O)—R—COOA or (ii) a combination of aliphatic monovalent acyl groups and groups of the formula —C(O)—R—COOA, wherein R is a divalent aliphatic or aromatic hydrocarbon group and A is hydrogen or a cation, and b) from 0.05 to 20 percent of at least one salt of a fatty acid, based on the weight of the dispersed esterified cellulose ether, wherein the median particle size, d50, of the dispersed esterified cellulose ether particles is up to 7 micrometers, such median particle size (d50) being the size at which 50 mass percent of the particles have a smaller equivalent diameter and 50 mass percent have a larger equivalent diameter.

Abstract: Provided is a solid preparation showing improved stability of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea and a salt thereof in the solid preparation, and a method of stabilizing the compound in a solid preparation. A tablet containing not less than 25 mass % of the compound; a solid preparation containing (1) the compound, and (2) a fat and oil-like substance having a low melting point, which is selected from polyethylene glycol, glycerol monostearate and triethyl citrate; a method of stabilizing the compound in a tablet, including adding not less than 25 mass % of the compound; and a method of stabilizing the compound, including adding a fat and oil-like substance having a low melting point, which is selected from polyethylene glycol, glycerol monostearate and triethyl citrate to a solid preparation containing the compound.

Abstract: Disclosed is confectionery having a transparent or translucent hard candy shell and a water-in-oil emulsion centerfill. Also disclosed is a sugar-free liquid edible composition and use in confectionery products.

Abstract: An aqueous, liquid or semi-liquid pharmaceutical or dietary composition, including at least one L-arginine salt on the basis of at least one gram of the salt per dosage unit. Adding the quantity of water necessary to dissolve an arginine salt, maltitol and, optionally, an alcohol or an alcoholate, ensures the removal of the bitterness from the liquid or semi-liquid compositions made from salified arginine. This specific composition allows considerable doses of arginine to be taken directly via oral administration, by drinking, without adding additional water. Also, a food composition containing a dietary composition as defined above.

Abstract: Provided is a method of forming a polymer, comprising (a) providing a reaction mixture comprising (i) one or more vinyl monomers, (ii) one or more pH-sensitive inhibition systems, (iii) one or more initiators, and (iv) water; (b) establishing conditions in said reaction mixture such that a free radical polymerization of said vinyl monomer occurs at a location, and (c) after steps (a) and (b) and prior to completion of said free radical polymerization, changing the pH of said reaction mixture to increase the rate of generation of said free radical polymerization at the location of said free radical polymerization.

Abstract: The present invention provides a therapeutic composition comprising a synergistic combination of caffeine, ginkgo biloba, and ?-phenylethylamine (PEA) or its salt. The invention is also directed to oral dosage forms containing said composition, and to a method of treatment of a psychological, psychiatric, behavioral and/or neurodevelopmental disorder comprising the administration of said compositions and dosage forms to a patient in need thereof.

Abstract: Methods for treating and diagnosing psychiatric affective disorders, e.g., an affective disorder associated with aberrant Sonic Hedgehog (Shh) signaling, by administering to the subject a therapeutically effective amount of an antagonist to Smoothened (Smo), an antagonist to Patched-1 (Ptch-1) and/or an antagonist to Shh.

Abstract: The present invention relates to pharmaceutical compositions comprising dimethyl fumarate and a pharmaceutically acceptable agent which inhibits the enzyme catalyzed degradation of dimethyl fumarate.

Abstract: An effervescent chewable dosage form that comprises a pH neutralization agent, an acid, and an effervescent agent. The chewable dosage form can also further comprise simethicone, a sweetener, and a lubricant. The pH neutralization agent can be calcium carbonate, the acid can be citric acid and the effervescent agent can be sodium bicarbonate.

Abstract: MPO1 and MPO2 can be regulated for either decreasing or increasing alkaloid levels in plants, in particular in Nicotiana plants. In particular, suppressing or overexpressing one or more of MPO1 and MPO2 may be used to decrease or increase nicotine and nicotinic alkaloid levels in tobacco plants. Suppression or overexpression of one or more of MPO1 and MPO2 may be used in combination with modification of expression of other genes encoding enzymes on the nicotinic alkaloid biosynthetic pathway such as A622, NBB1, PMT, and QPT.

Abstract: The present invention relates to compositions and methods for eye and contact lens care. More particularly, the invention relates to ophthalmic compositions which contain at least one bioflavonoid component for ocular care, preserving ophthalmic solutions and/or disinfecting contact lenses.

Abstract: The invention provides oral care compositions comprising a mixture of tetrabasic zinc halide and trimethylglycine, in free or orally acceptable salt form. Methods of making and using the compositions are also provided.